Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Nicoya is a famous blue zone. DNA aging estimates tell a more complicated story

26

Aug 2026

Nicoya is a famous blue zone. DNA aging estimates tell a more complicated story

Researchers developed a SuperLearner framework that combines established epigenetic clocks with machine learning to compare DNA methylation-based aging in residents of Costa Rica’s Nicoya Blue Zone with other Costa Ricans. Initial calibration suggested a modest younger epigenetic age among Nicoyans, but accounting more closely for age distribution substantially reduced the apparent advantage, highlighting the importance of population-specific calibration in longevity research.

GLP-1 drugs may reshape obesity care, but clinicians still have questions

26

Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

Vagus nerve stimulation may enhance long-term motor learning

26

Aug 2026

Vagus nerve stimulation may enhance long-term motor learning

Do you ever feel like sometimes you can master a new dance step almost immediately, while other times you struggle to nail it despite repeated practice? This might be due to skill or effort, but also to something less obvious: whether the brain is in a state that allows learning to take hold.

Why living to 100 may depend on far more than diet and exercise

25

Aug 2026

Why living to 100 may depend on far more than diet and exercise

A critical narrative review found that healthy diets, regular physical activity, strong social ties, and psychological well-being can support healthier aging and reduce premature mortality, but none has been shown to reliably determine who reaches 100. The authors argue that exceptional longevity arises from complex interactions among biological resilience, genetics, social and environmental conditions, lifelong exposures, and chance rather than any universal lifestyle formula.

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

25

Aug 2026

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

Critical Path Institute® (C-Path) today announced the publication of "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.